Subclinical renal allograft rejection and protocol biopsies: Quo vadis?

Nature Clinical Practice Nephrology

Volumn 4, Issue 3, 2008, Pages 134-135

  Nankivell, Brian J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Protocol biopsy; Renal transplant; Subclinical rejection; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

CADAVER KIDNEY; CLINICAL PROTOCOL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; LIVING DONOR; NOTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

BIOPSY; CLINICAL PROTOCOLS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION;

EID: 39749151262     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0701     Document Type: Note

References (5)

1. Nankivell BJ and Chapman JR (2006) The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 6: 2006-2012
2. Rush D et al. (1998) Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 9: 2129-2134
3. Gloor JM et al. (2002) Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 73: 1965-1968
4. Kurtkoti J et al.: The utility of 1 and 3 month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant, in press
5. Nankivell BJ et al. (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333